Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anaerobutyricum soehngenii CH-106
- Development stage
- Unknown
- Lead developer
- Caelus Pharmaceuticals
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Anaerobutyricum soehngenii CH-106 is a live biotherapeutic product (LBP) consisting of an encapsulated, butyrate-producing anaerobic bacterium. Formerly classified as *Eubacterium hallii*, CH-106 is a tetracycline-sensitive isogenic derivative of the parental strain A. soehngenii L2-7. It is being developed by Amsterdam UMC in collaboration with Caelus Health and Wageningen University for the treatment of cardiometabolic disorders, including insulin resistance, type 2 diabetes, and non-alcoholic steatohepatitis (NASH). The therapeutic mechanism involves the production of butyrate, a short-chain fatty acid that modulates the gut microbiome and stimulates the production of intestinal glucagon-like peptide-1 (GLP-1), thereby improving glucose metabolism and insulin sensitivity. The strain has received a no-objection letter from the U.S. FDA regarding its self-affirmed GRAS (Generally Recognized as Safe) status.
- Other names
- Eubacterium hallii CH-106Anaerobutyricum soehngenii
02
Targets
Beyond the preview
Go deeper on Anaerobutyricum soehngenii CH-106.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Anaerobutyricum soehngenii CH-106.